Vertex price target raised to $146 from $125 at Piper Jaffray Piper Jaffray raised its price target for Vertex Pharmaceuticals shares to $146 citing continued Kalydeco growth after the company issued 2015 guidance. Piper reiterates an Overweight rating on Vertex.
Vertex sees 2015 Kalydeco revenue $560M-$580M Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. It said the increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses recorded in 2015. Vertex said entered 2015 with approximately $1.4B in cash, cash equivalents and marketable securities. Anticipated 2015 Kalydeco net revenues reflect: Use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; Use of KALYDECO in people in the United States with the R117H mutation following FDA approval in late 2014; The completion of reimbursement discussions for gating mutations in certain European countries; Use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015.